CAMBRIDGE, Mass., June 2 /PRNewswire-FirstCall/-- Transkaryotic Therapies,
Inc. (Nasdaq: TKTX) today announced that it has named Marcio Voloch, Ph.D.
Vice President, Process Development. In this newly created position, he will
have overall responsibility for directing and coordinating all the process
development activities at TKT including cell culture, purification,
formulation and analytical development of recombinant proteins.
Dr. Voloch was formerly Group Director, Molecular Biology and Process
Research within the Biotechnology Development Department at Schering Plough
Research Institute. During his fourteen year tenure at Schering-Plough, he
led the design, development and validation strategy of a new commercial
production process for Schering's recombinant interferon alfa product.
Additionally, he oversaw the process and product characterization development
for pegylated interferon alfa, which resulted in the first FDA-approved
pegylated interferon. Dr. Voloch also held research and technical positions
at Hoffman-La Roche, Inc., Celgene Corporation and Purdue University. He
received a B.Sc. in Chemical Engineering from Israel Institute of Technology
and a Ph.D. in Chemical Engineering from Purdue University.
"Our product pipeline has grown to a point that it requires us to place
greater emphasis on commercial processes," said David Pendergast, Ph.D.,
Executive Vice President and Chief Operating Officer of TKT. "With Marcio's
skills and over twenty years experience in the pharmaceutical industry, he
will expand our process development initiatives, spearhead the development of
cost-effective manufacturing processes for our new products, and accelerate
our ongoing transition from roller bottles to bioreactors. It is with great
pleasure that we welcome Marcio to TKT."
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and Latin America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including whether TKT
will be able to successfully manage process development activities, and other
factors set forth under the caption "Certain Factors Which May Affect Future
Results" in the company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2004, which is on file with the Securities and Exchange Commission
and are incorporated herein by reference. While the company may elect to
update forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, even if its expectations
change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
CONTACT:
Justine E. Koenigsberg
Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Corporate
Communications Specialist, +1-617-349-0205, both of Transkaryotic
Therapies, Inc.
Logo: NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO AP Archive:
http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or
212-782-2840
|
